Urinary Tract Infection Market Size & Outlook, 2025-2033

Urinary Tract Infection Market Size

The global urinary tract infection market size was valued at USD 9.55 billion in 2024 and is expected to grow from USD 9.85 billion in 2025 to USD 12.67 billion by 2033, growing at a CAGR of 3.2% during the forecast period (2025-2033).

Factors such as combinational drug launch, prioritization of new markets and Improved R&D significantly drives the urinary tract infection market demand by 2031.

An infection of the kidneys, ureters, bladder, or urethra is a urinary tract infection (UTI). The introduction of novel urinary incontinence devices, the rise in demand for minimally invasive procedures, the transition from traditional solutions to novel urinary incontinence products, and the effectiveness in preventing hospital-acquired infections (HAIs) all contribute to the market's expansion globally. However, a lack of knowledge about urinary incontinence devices, post-operative difficulties, and increased worries about disposable goods limit market expansion. In the upcoming years, there will be new opportunities due to the rising healthcare costs in developing nations and the increased technology integration.

To get more insights about this report Download Free Sample Report

Urinary Tract Infection Market Growth Factors

Combinational Drug Launch

The urinary tract infection market is anticipated to rise due to increased research and development (R&D) of a novel class of antibiotics for urinary tract infections.

• For instance, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting and Expo in August 2020, researchers from California Polytechnic State University presented the creation of a novel class of antibiotics for urinary tract infections that target bacterial iron uptake. Recarbrio (imipenem, cilastatin, and sulbactam), an antibacterial medicinal product, was also approved by the U.S. Food and Drug Administration in July 2019 for use by individuals with complex urinary tract infections (UTI) and complicated intra-abdominal infections (cIAI).

A novel antibiotic combination medication for treating individuals with cUTI received FDA approval in August 2017. Meropenem, an antibiotic, and vaborbactam, a new beta-lactamase inhibitor, are both components of the medication Vabomere. According to the FDA's press announcement, 545 UTI patients, including those with acute pyelonephritis, participated in a multi-center, randomized phase 3 clinical trial where Vabomere statistically outperformed another antibiotic/beta-lactamase combination medication (kidney infection). Introducing more effective combination medications is anticipated to accelerate the market's expansion for urinary tract infections.

Market Restraining Factors

Requirements for Complete Regulation

The global market for treating urinary tract infections is anticipated to experience growing challenges due to complex regulatory regulations. The clinical approval process, such as clinical trial design, interpretation, and analysis, distinguishes the clinical trial of an antibiotic from that of other medicinal medications. To obtain clearance for the product alongside already approved antibacterial medications, the sponsor must complete non-inferiority trials. Clinical trials for developing antibacterial medications are intricate and call for a thorough, moral, and scientific approach. These elements are anticipated to limit market growth during the forecast.

Market Opportunity

Prioritization of New Markets and Improved R&d

Urinary tract infections are becoming more common, which is anticipated to help the market grow. A study entitled "Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI," which was conducted at the Microbiology department of a tertiary healthcare hospital in Mumbai and published in 2018, found that the overall prevalence of UTI was 33.54%, with 66.78% of cases coming from females and 33.22% from males.

Additionally, R&D in urinary tract infections is anticipated to provide companies in the global urinary tract market with lucrative growth prospects.

• For instance, in May 2020, researchers from the Vrije Universiteit Amsterdam in the Netherlands reported that urinary tract infections could be distinguished from other conditions in a high-risk pediatric population to diagnose using an electronic nose and volatile organic compound profiling. Increasing R&D for quick and accurate diagnosis results in a rise in diagnosed cases and improves patient care.

Regional Insights

North America is the major revenue contributor and is expected to grow at a CAGR of 3.65% during the forecast period. North America and Latin America make up most of the market in the Americas. The US and Canada are part of the North American market. Due to the rapid development of diagnostic and therapeutic goods and the increased incidence of renal and urogenital illnesses, the Americas now account for most of the global market. The U.S. has the most significant market share for urinary tract infections (UTIs). The main factors influencing the urinary tract infection market growth in this region are the existence of cutting-edge healthcare facilities, growing healthcare costs, and an increase in the prevalence of bacterial infections among the local population of senior women.

Europe Urinary Tract Infection Market Trends

Europe is expected to grow at a CAGR of 3.90% during the forecast period. In terms of revenue, Europe is the second-largest regional market. In Europe, urinary diseases place a heavy economic strain. According to a WHO bulletin, the EU5 (France, Germany, Italy, Spain, and the UK) high-income countries spend 2 to 3 percent of their yearly health budget on treating urinary illness. Rising awareness of urinary tract disorders, increased educational activity, and the availability of various diagnostic and therapeutic approaches to manage infection are the driving forces behind the market expansion in this region. Additionally, various medical factors like pregnancy, low immunity, aging, kidney transplant patients, and unhygienic behaviors raise a woman's risk of developing a urinary tract infection.

Asia-Pacific is anticipated to have the quickest rate of UTI market growth during the projection period. The growing economies and densely populated nations like China, India, and South Korea are to blame for this. Due to several pharmaceutical manufacturing companies, an increase in patients, and growing public awareness of the treatment options for urinary health conditions, the Asia-Pacific region is anticipated to experience the highest growth in the global market during the forecast period. The rising demand for UTI diagnosis and treatment methods in private hospitals and clinics is a further opportunity for the market to grow.

The Middle East and Africa comprise the two regions that include the Middle East and Africa market. The expanding healthcare infrastructure, the underdeveloped market in this area, and the steadily rising product demand have all contributed to the market's expansion.

Drug Class Insights

The global market share is bifurcated into quinolones, cephalosporin, aminoglycosides, β-lactam, azoles, penicillin, and others. The quinolones segment is the highest contributor to the market and is estimated to grow at a CAGR of 4.10% during the forecast period.Ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin are further subgroups of quinolones. There are four types of cephalosporin: cedar, cefdinir, and cefditoren. A-lactam is divided into cefdinir, cefaclor, and cefpodoxime-proxetil, as well as amoxicillin-clavulanate. The only available treatments for urinary tract infections are antibiotics. A wide variety of antibiotics is provided depending on the infection's severity.

• For instance, fluoroquinolones, trimethoprim/sulfamethoxazole, and aminoglycosides are typically used as the first line of treatment for uncomplicated urinary tract infections.

Due to the rise in bacteria that are resistant to antibiotics and the overuse of medicines, complex UTIs are anticipated to become more commonplace in the future. Doctors typically prescribe quinolones to treat difficult UTI situations. The second-most frequent medication administered for challenging UTI patients is cephalosporin. Since doctors most frequently prescribe quinolones during the projected period, the market for these medications is anticipated to increase enormously. Levofloxacin, enoxacin, and ciprofloxacin are some of the most often prescribed drugs. Quinolone medication segment expansion is expected to be aided by their potency against multidrug-resistant pathogens and optimal pharmacokinetics availability in the oral dosage form.

Cefuroxime axetil's early clinical trials for single-dose, short-term therapy seems promising. In vitro susceptibility testing guides the use of parenteral cephalosporins, which are only used against more resistant strains or in hospitalized patients with upper urinary tract infections. Ceftazidime and cefsulodin, two more recent medications, have proven effective against P. aeruginosa infections. Cephalosporins are still used to treat urinary tract infections despite being more expensive than other antibiotics. Aminoglycosides are used to treat severe infections of the urinary tract and abdomen.

Application Insights

The global urinary tract infection industry share is bifurcated into urethritis, cystitis, pyelonephritis, and others. The urethritis segment is the highest contributor to the market and is estimated to grow at a CAGR of 4.05% during the forecast period. Both common symptoms are the lower urinary tract infection and urethral enlargement caused by urethritis, a gonococcal or nongonococcal infection. Urine discharge results from urethritis. According to the Antimicrobe Organization, approximately 4 million Americans are said to be plagued by urethritis every year. In addition, 89 million new cases of nongonococcal urethritis and 62 million new cases of N. gonorrhea yearly are recorded globally.

The market for urogenital tract infections' second-largest application is cystitis. Inflammation, irritability, and redness are all symptoms of cystitis. Given that women's urethras are shorter than men's, which makes it simpler for bacteria to enter the bladder, women are considerably more prone than males to get cystitis. At least once a year, 10 out of every 100 women get cystitis. Within a year, it returns in 50% of those women. Approximately 3 to 8 million women in the US today have interstitial cystitis (IC), and 1 to 4 million men. This is according to the Interstitial Cystitis Association. The market is growing due to the rising incidence of cystitis among a sizable population.

Known as pyelonephritis, this kidney infection starts in the urethra or bladder and spreads to both kidneys. In the US, acute pyelonephritis occurs at a rate of 3–4 occurrences per 10,000 males and 15–17 cases per 10,000 females each year, according to the National Center for Biotechnology Information's 2020 study.

Pathogen Insights

The global market share is bifurcated into escherichia coli, staphylococcus saprophyticus, klebsiella pneumonia, proteus mirabilis, enterococcus faecalis, and others. The escherichia coli segment is the highest contributor to the market and is estimated to grow at a CAGR of 3.95% during the forecast period. One of the common causes of urinary tract infections is Escherichia coli (UTI). 2019 saw the most significant market share, 65.6%, go to Escherichia coli. This expansion is a result of E. coli's rising antibiotic resistance.

• For instance, data on Cotrimoxazole antibiotic resistance information in Asian countries was released in 2018 by the National Center for Biotechnology Information. The article stated that UTIs are treated with the antibiotic Cotrimoxazole. The publication said that resistance to the antibiotic Cotrimoxazole occurs at 10-15% in Japan, with resistance rates of approximately 30% in China and South Korea, while E. coli resistance rates in Europe and the Mediterranean region are much lower.

End-User Insights

The global urinary tract infection market share is bifurcated into hospital, clinical, self-administered, and others. The hospital segment is the major contributor to the market and is estimated to grow at a CAGR of 3.60% during the forecast period. In 2019, hospitals held the most significant market share. Hospitals provide patients with various treatment, diagnostic, and consultation choices at one visit. The rise in hospitals and the incidence of urinary illnesses, including interstitial cystitis and hematuria, are to blame for this segment's market expansion. Around 250,000 occurrences of pyelonephritis are reported annually in the US, and 7% of those cases, according to the National Center for Biotechnology Information 2019 release, necessitate hospital admission for appropriate care. Small and large hospitals are quickly adopting cutting-edge technology, and there is increased public knowledge of disease detection and treatment.

Clinics are predicted to be the second-largest end-user category after hospitals. Increased patient visits for routine health checks and increased urinary health and sanitation awareness fuel the market's expansion.

Distribution Channel Insights

The global urinary tract infection market share is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacy segment shows dominance in the distribution channel for the urinary tract infection market, mainly due to the high availability of prescription antibiotics and OTC drugs for the treatment of urinary tract infections. This is where customers find convenience and access for the immediate alleviation of urinary tract infection symptoms or continued management of the condition. This also provides personal advice from pharmacists, increasing patient compliance and satisfaction. The availability of OTC urinary tract infection drugs helps consumers to self-treat mild symptoms without a prescription, thus further promoting the segment's prominence in the market.

List of key players in Urinary Tract Infection Market

1. Pfizer Inc.
2. GlaxoSmithKline plc
3. Merck & Co., Inc.
4. Novartis AG
5. Johnson & Johnson
6. Sanofi S.A.
7. AstraZeneca plc
8. Abbott Laboratories
9. Bristol-Myers Squibb Company
10. Eli Lilly and Company
11. Cipla Limited
12. Sun Pharmaceutical Industries Ltd.
13. Astellas Pharma Inc.
14. Teva Pharmaceutical Industries Ltd.
15. Reddy's Laboratories Ltd.

To get more findings about this report Download Market Share

Recent Developments

• October 2021- Tebipenem HBr tablets were submitted for FDA approval in a new drug application (NDA) by Spero Therapeutics Inc. for treating complex urinary tract infections (cUTI), including pyelonephritis, brought on by susceptible microorganisms.
• September 2021- Biapenem was introduced by BDR Pharma, one of India's top generic drug makers, to treat patients with complex urinary tract infections, lower respiratory infections, and intra-abdominal infections.